An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?

Dakin, 2015, The influence of cost‐effectiveness and other factors on nice decisions, Health Economics, 24, 1256, 10.1002/hec.3086 Neumann, 2009, Costing and perspective in published cost-effectiveness analysis, Medical Care, 47, S28, 10.1097/MLR.0b013e31819bc09d Sanders, 2016, Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine, JAMA, 316, 1093, 10.1001/jama.2016.12195 Devlin, 2017, QALYs as a measure of value in cancer, Journal of Cancer Policy, 11, 19, 10.1016/j.jcpo.2016.09.005 Garrison, 2017, Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis, Value in Health, 20, 213, 10.1016/j.jval.2016.12.005 Garrison, 2016 Cook, 2011, Real option value and path dependence in oncology innovation, International Journal of the Economics of Business, 18, 225, 10.1080/13571516.2011.584428 2012 Sanchez, 2012, The option value of innovative treatments in the context of chronic myeloid leukemia, The American Journal of Managed Care, 18, s265 Lakdawalla, 2012, How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies, Health Affairs, 31, 676, 10.1377/hlthaff.2011.1300 Shafrin, 2017, Patient versus physician valuation of durable survival gains: implications for value framework assessments, Value in Health, 20, 217, 10.1016/j.jval.2016.11.028 Shih, 2016, Reconsidering the economic value of multiple sclerosis therapies, The American Journal of Managed Care, 22, e368 Lakdawalla, 2017, The insurance value of medical innovation, Journal of Public Economics, 145, 94, 10.1016/j.jpubeco.2016.11.012 Lakdawalla, 2010, An economic evaluation of the war on cancer, Journal of Health Economics, 29, 333, 10.1016/j.jhealeco.2010.02.006 Cookson, 2017, Using cost-effectiveness analysis to address health equity concerns, Value in Health, 20, 206, 10.1016/j.jval.2016.11.027 Lakdawalla, 2018, Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force report [3], Value in Health, 21, 131, 10.1016/j.jval.2017.12.007 O’Brien, 2002, Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods, Statistical Methods in Medical Research, 11, 455, 10.1191/0962280202sm304ra 2017 Goeree, 2016, Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes, Journal of medical Economics, 1 Canadian Cancer Society. Cancer statistics at a glance. Available from: http://www.cancer.ca/en/cancer-information/cancer-101/cancer-statistics-at-a-glance/?region=on. Jemal, 2011, Global cancer statistics, CA : A Cancer Lournal for Clinicians, 61, 69 Penrod, 2014, Survival of US Medicare patients with advanced non-small cell lung cancer by line of therapy, American Society of Clinical Oncology, 32, 6582, 10.1200/jco.2014.32.15_suppl.6582 Topalian, 2012, Safety, activity, and immune correlates of anti–PD-1 antibody in cancer, The New England Journal of Medicine, 366, 2443, 10.1056/NEJMoa1200690 Wang, 2014, In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates, Cancer Immunology Research, 2, 846, 10.1158/2326-6066.CIR-14-0040 Ribas, 2012, Tumor immunotherapy directed at PD-1, The New England Journal of Medicine, 366, 2517, 10.1056/NEJMe1205943 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer, The New England Journal of Medicine, 373, 123, 10.1056/NEJMoa1504627 Goulart, 2011, A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer, Value in Health, 14, 836, 10.1016/j.jval.2011.04.004 Mitera, 2014, Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non–small-cell lung cancer, Journal of oncology practice, 10, e130, 10.1200/JOP.2013.001206 Sher, 2012 Dubois, 2017 Yaldo, 2014, The cost of absenteeism and short-term disability associated with colorectal cancer: a case–control study, Journal of Occupational and Environmental Medicine, 56, 848, 10.1097/JOM.0000000000000186 Van Houtven, 2010, Economic burden for informal caregivers of lung and colorectal cancer patients, The Oncologist, 15, 883, 10.1634/theoncologist.2010-0005 Thornton, 2017, The option value of innovative treatments for non–small cell lung cancer and renal cell carcinoma, American Journal of Managed Care, 23, e340 Brahmer, 2017 Schnipper, 2016, Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received, Journal of Clinical Oncology, 34, 2925, 10.1200/JCO.2016.68.2518 Philipson, 2010, Terminal care and the value of life near its end, National Bureau of Economic Research American College of Rheumatology, 2017 Hirth, 2000, Willingness to pay for a quality-adjusted life year in search of a standard, Medical Decision Making, 20, 332, 10.1177/0272989X0002000310 Mason, 2008, Willingness to pay for a QALY: past, present and future, Expert Review of Pharmacoeconomics & Outcomes Research, 8, 575, 10.1586/14737167.8.6.575 Nimdet, 2015, A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?, PLoS One, 10, e0122760, 10.1371/journal.pone.0122760 Ryen, 2015, The willingness to pay for a quality adjusted life year: a review of the empirical literature, Health Economics, 24, 1289, 10.1002/hec.3085 Chandra, 2016, Utility of cancer value frameworks for patients, payers, and physicians, JAMA, 315, 2069, 10.1001/jama.2016.4915 Weinstein, 1977, Foundations of cost-effectiveness analysis for health and medical practices, The New England Journal of Medicine, 296, 716, 10.1056/NEJM197703312961304 Acemoglu, 2004, Market size in innovation: theory and evidence from the pharmaceutical industry, The Quarterly Journal of Economics, 119, 1049, 10.1162/0033553041502144 Canadian Agency for Drugs and Technologies in Health. 2017. Available from: https://www.cadth.ca/pcodr/about-pcodr. Woolhandler, 2003, Costs of health care administration in the United States and Canada, The New England Journal of Medicine, 349, 768, 10.1056/NEJMsa022033 Ramsey, 2008, How should we value lives lost to cancer?, Journal of the National Cancer Institute, 100, 1742, 10.1093/jnci/djn434 Martin, 2015, Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in checkmate 017 Danzon, 2018, Objectives, budgets, thresholds, and opportunity costs—a health economics approach: an ISPOR Special Task Force report [4], Value in Health, 21, 140, 10.1016/j.jval.2017.12.008